AWMS
TEVA icon

Advocacy Wealth Management Services’s Teva Pharmaceuticals TEVA Stock Holding History

Advocacy Wealth Management Services’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-200
Closed -$5K – 252
2017
Q3 		$5K Buy
200
+100
+100% +$2.25K ﹤0.01% 240
2017
Q2 		$3K Hold
100
– – ﹤0.01% 253
2017
Q1 		$3K Hold
100
– – ﹤0.01% 281
2016
Q4 		$4K Sell
100
-35
-26% -$1.4K ﹤0.01% 262
2016
Q3 		$6K Hold
135
– – ﹤0.01% 313
2016
Q2 		$7K Sell
135
-245
-64% -$13K ﹤0.01% 324
2016
Q1 		$20K Hold
380
– – 0.01% 295
2015
Q4 		$25K Buy
+380
New +$23.5K 0.03% 247
2013
Q3 		$19K Hold
500
– – 0.05% 187
2013
Q2 		$20K Buy
+500
New +$19.5K 0.08% 144

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Advocacy Wealth Management Services's TEVA Position: Q4 2017 in Review

Advocacy Wealth Management Services sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 200 shares — an estimated $5K sold.

Advocacy Wealth Management Services first reported a position in TEVA in Q2 2013 and held it in 10 quarters. The position peaked at $25K in Q4 2015. 507 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Advocacy Wealth Management Services reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Advocacy Wealth Management Services sold 200 Teva Pharmaceuticals shares in Q4 2017, an estimated $5K.
  • Advocacy Wealth Management Services first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 10 quarters.
  • Advocacy Wealth Management Services's Teva Pharmaceuticals position peaked at $25K in Q4 2015.
  • 507 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Advocacy Wealth Management Services's 13F filing for Q4 2017, filed 12 Jan 2018.